

# 1 **The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout**

## 2 **Authors:**

3 1. Ahmed Zaqout<sup>1,2</sup>

4 E-mail: azaqout@hamad.qa

5 2. Joanne Daghfal<sup>1</sup>

6 E-mail: jnader@hamad.qa

7 3. Israa Alaqad<sup>1</sup>

8 E-mail: ialaqad@hamad.qa

9 4. Saleh A.N. Hussein<sup>1</sup>

10 E-mail: shussein4@hamad.qa

11 5. Abdullah Aldushain<sup>1</sup>

12 E-mail: aaldushain@hamad.qa

13 6. Muna A. Almaslamani<sup>1,2</sup>

14 E-mail: @hamad.qa

15 7. Mohammed Abukhattab<sup>1,2</sup>

16 E-mail: mabukhattab@hamad.qa

17 8. Ali S. Omrani<sup>1,2\*</sup>

18 E-mail: @hamad.qa

19 <sup>1</sup>Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar

20 <sup>2</sup>Division of Infectious Diseases, Hamad Medical Corporation, Doha, Qatar

21 \*Corresponding author

## 22 **Corresponding Author:**

23 Dr Ali S. Omrani (ORCID ID 0000-0001-5309-6358)

24 PO Box 3050

25 Communicable Diseases Center

26 Hamad Medical Corporation

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

27 Doha, Qatar

28 Tel: +974 40254065

29 E-mail: aomrani@hamad.qa

30 **Running title**

31 BNT162b2 in Qatar

32 **Keywords**

33 COVID-19; SARS-CoV-2; coronavirus; vaccine; BNT162b2; mRNA; Qatar

34 **Abstract**

35 **Objective**

36 We herein report the initial impact of a national BNT162b2 rollout on SARS-CoV-2  
37 infections in Qatar.

38 **Methods**

39 We included all individuals who by 16 March 2021 had completed  $\geq 14$  days of follow up  
40 after the receipt of BNT162b2. We calculated incidence rates (IR) and their 95% confidence  
41 intervals (CI), during days 1–7, 8–14, 15–21, 22–28, and  $>28$  days post-vaccination. Poisson  
42 regression was used to calculate incidence rate ratios (IRR) relative to the first 7-day post-  
43 vaccination period.

44 **Results**

45 We included 199,219 individuals with 6,521,124 person-days of follow up. SARS-CoV-2  
46 infection was confirmed in 1,877 (0.9%), of which 489 (26.1%) were asymptomatic and 123  
47 (6.6%) required oxygen support. The median time from first vaccination to SARS-CoV-2  
48 confirmation was 11.9 days (IQR 7.7–18.2). Compared with the first 7-day post-vaccination  
49 period, SARS-CoV-2 infections were lower by 65.8–84.7% during days 15–21, days 22–28,  
50 and  $>28$  days ( $P < 0.001$  for each). For severe COVID-19, the incidence rates were 75.7–  
51 93.3% lower ( $P < 0.001$  for each) during the corresponding time periods.

52 **Conclusion**

53 Our results are consistent with an early protective effect of BNT162b2 against all degrees of  
54 SARS-CoV-2 severity.

## 55 **Background**

56 A two-dose regimen of BNT162b2, the Pfizer-BioNTech COVID-19 mRNA vaccine, was  
57 shown to reduce the risk of SARS-CoV-2 by around 95% in a randomized clinical trial, and  
58 in a mass national vaccination program.[1, 2] On 23 December 2020, Qatar started a national  
59 BNT162b2 rollout programme, in addition to existing COVID-19 public health control  
60 measures. The rollout initially prioritised healthcare workers, individuals aged  $\geq 50$  years, and  
61 those with chronic or immune suppressive medical conditions. We herein report the initial  
62 impact of BNT162b2 on SARS-CoV-2 infections in Qatar.

## 63 **Methods**

64 SARS-CoV-2 infections were confirmed using real-time PCR on upper or lower respiratory  
65 samples. BNT162b2 was supplied in multidose 0.45 mL vials, and was stored, prepared and  
66 administered according to the manufacturer's instructions.[3] We used the COVID-19  
67 database at the Communicable Disease Center, Hamad Medical Corporation, to  
68 retrospectively collate clinical and outcome data for all individuals who by 16 March 2021  
69 had completed  $\geq 14$  days of follow up after the receipt of at least one dose of BNT162b2.  
70 Confirmed COVID-19 and severe COVID-19 were defined according to the Food and Drug  
71 Administration criteria.[1]  
72 We calculated SARS-CoV-2 infection incidence rates (IR), and their 95% confidence  
73 intervals (CI), per 100,000 person-days during five time-period: days  $< 7$  days, 8–14 days,  
74 15–21 days, 22–28 days, and  $> 28$  days from receipt of the first BNT162b2 dose. Individuals  
75 stopped contributing person-days once SARS-CoV-2 infection was confirmed or at the study  
76 end date, whichever came first. We used Poisson regression to calculate incidence rate ratios  
77 (IRR) and their 95% CI for the latter four time-periods relative to IR during the first seven  
78 days from the first BNT162b2 dose. Statistical analyses were performed using Stata  
79 Statistical Software, Release 16.1 (StataCorp., College Station, Texas).

## 80 **Results**

81 The included 199,219 individuals contributed 6,521,124 person-days of follow up. SARS-  
82 CoV-2 infection was confirmed in 1,877 (0.9%), of which 365 (19.5%) occurred after receipt  
83 of a second BNT162b2 dose. The median time from first vaccination to SARS-CoV-2  
84 confirmation was 11.9 days (IQR 7.7–18.2). Compared with those without SARS-CoV-2  
85 infection, infected individuals were significantly older, and more likely to have co-existing  
86 medical conditions (Table). Cough (1,018, 54.2%) and fever (745, 39.7%) were the most  
87 frequent presenting symptoms, while infections were asymptomatic in 489 (26.1%). High-  
88 flow nasal oxygen or non-invasive ventilation was required for 28 (1.5%) individuals,  
89 invasive mechanical ventilation for 11 (0.6%), and oxygen via face mask or nasal cannula for  
90 84 (4.5%). Five individuals (median age 81 years, range 52–93) had fatal COVID-19, all with  
91 multiple comorbidities, and most with infected household contacts. For fatal COVID-19  
92 cases, symptoms started after a median of 12 days (range 7–25) after the first BNT162b2  
93 dose.

94 SARS-CoV-2 IR was 28.63/100,000 person-days (95% CI 25.96–31.58) during the first  
95 seven days post-vaccination, and 27.19/100,000 person-days (95% CI 25.32–29.2) during  
96 days 8–14. Compared with the first 7-day post-vaccination period, the IR was significantly  
97 lower during days 15–21 (IRR 0.342, 95% CI 0.297–0.394,  $P < 0.001$ ), days 22–28 (IRR  
98 0.171, 95% CI 0.142–0.205,  $P < 0.001$ ), and >28 days (IRR 0.153, 95% CI 0.129–0.182,  $P$   
99  $< 0.001$ ). Similarly, in comparison with the first 7-day post-vaccination period, the IRR for  
100 severe COVID-19 decreased significantly during days 15–21 (IRR 0.243, 95% CI 0.136–  
101 0.434,  $P < 0.001$ ), days 22–28 (IRR 0.171, 95% CI 0.087–0.335,  $P < 0.001$ ), and >28 days  
102 (IRR 0.067, 95% CI 0.028–0.161,  $P < 0.001$ ) (Figure).

103 Our findings are consistent with those shown previously in a community setting and in  
104 healthcare workers, but our report is the first to include an entire national cohort of

105 BNT162b2 recipients.[2, 4] We also demonstrated a significant reduction in risk of severe  
106 COVID-19. This is particularly important, given its potential to reduce COVID-19-associated  
107 morbidity and mortality, and decrease its impact on healthcare resource utilization.[5]  
108 We found relatively high SARS-CoV-2 IR during the first two weeks following receipt of the  
109 first BNT162b2 dose. While the vaccine's protective effect may not be apparent during the  
110 first two weeks after BNT162b2 vaccination,[1] recipients may wrongly perceive themselves  
111 to be at a reduced risk of SARS-CoV-2 infection and become less adherent to  
112 nonpharmacological preventive measures such as social distancing and face covering.[6]  
113 Careful education and counselling during the vaccination process could help efforts to  
114 minimise such risk compensation behaviour.

115 SARS-CoV-2 variants of concerns (VOC) such B.1.1.7 lineage (first reported in the United  
116 Kingdom), and B.1.351 lineage (first reported in South Africa), are known to have been  
117 circulating in Qatar during the study's follow up period.[7] There has been concern that VOC  
118 may reduce the effectiveness of some COVID-19 vaccines.[8] However, BNT162b2 elicits  
119 high neutralising antibodies titres against B.1.1.7 and B.1.351 lineages.[9] Moreover, recently  
120 announced results from an ongoing phase 3 BNT162b2 randomised trial suggest it is highly  
121 effectiveness against B.1.351 lineage.[10]

122 Deaths in our study mostly occurred in older individuals with multiple co-morbidities.  
123 Vaccine effectiveness is generally lower in such groups.[2] Notably, infected household  
124 contacts were identified in three out of the five fatal COVID-19 cases, reinforcing the  
125 importance of wide vaccine rollout to maximise protection of the most vulnerable.[5]  
126 The limitations of this study include its observational nature and the lack of a non-vaccinated  
127 control group. We used the first 7-day post-vaccination period, during which no vaccine  
128 effectiveness is expected, as a reference to assess the vaccine's protective benefits in later  
129 time-periods. Overall, our results are consistent with an early protective effect of BNT162b2

130 against all degrees of SARS-CoV-2 severity. It is anticipated that, in addition to ongoing  
131 nonpharmacological interventions, broader vaccine coverage will contribute to the national  
132 and global pandemic control efforts.

### 133 **Ethical issues**

134 The study was approved by Hamad Medical Corporation's Institutional Review Board with a  
135 waiver of informed consent (MRC-01-21-207).

### 136 **Conflict of interests**

137 The authors declare no conflict of interests in relation to this manuscript.

### 138 **Funding**

139 The publication of this report was funded by Qatar National Library. No other funding was  
140 required.

### 141 **Acknowledgments**

142 We would like to thank Hussam Alsoub and Faraj S. Howady for their support during the  
143 preparation of this report.

### 144 **References:**

- 145 1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety  
146 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.*  
147 2020;383(27):2603-15. doi: 10.1056/NEJMoa2034577I.
- 148 2. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2  
149 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med.*  
150 2021. doi: 10.1056/NEJMoa2101765I.
- 151 3. Pfizer-BioNTech. Pfizer-BioNTech COVID-19 Vaccine Fact Sheet for Healthcare  
152 Providers Administering Vaccine (Vaccination Providers).  
153 <http://labeling.pfizer.com/ShowLabeling.aspx?id=14471> (accessed 10 Apr 2021).

- 154 4. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. Effectiveness of  
155 BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in  
156 Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN  
157 Study). SSRN. 2021. doi: 10.2139/ssrn.3790399I.
- 158 5. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What  
159 defines an efficacious COVID-19 vaccine? A review of the challenges assessing the  
160 clinical efficacy of vaccines against SARS-CoV-2. *Lancet Infect Dis.* 2021;21(2):e26-  
161 e35. doi: 10.1016/S1473-3099(20)30773-8I.
- 162 6. Brit Trogen, Arthur Caplan. Risk Compensation and COVID-19 Vaccines. *Ann Intern*  
163 *Med.* 2021. doi: 10.7326/M20-8251I.
- 164 7. The Peninsula Qatar. We are seeing positive COVID-19 cases in Qatar with new UK  
165 strain variant. [https://www.thepeninsulaqatar.com/article/10/03/2021/We-are-seeing-](https://www.thepeninsulaqatar.com/article/10/03/2021/We-are-seeing-positive-COVID-19-cases-in-Qatar-with-new-UK-strain-variant-Dr-Khal)  
166 [positive-COVID-19-cases-in-Qatar-with-new-UK-strain-variant-Dr-Khal](https://www.thepeninsulaqatar.com/article/10/03/2021/We-are-seeing-positive-COVID-19-cases-in-Qatar-with-new-UK-strain-variant-Dr-Khal) (accessed  
167 10 Apr 2021).
- 168 8. Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants — Clinical, Public  
169 Health, and Vaccine Implications. *N Engl J Med.* 2021. doi:  
170 10.1056/NEJMc2100362I.
- 171 9. Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias CR, Swanson KA, et al. Neutralizing  
172 Activity of BNT162b2-Elicited Serum. *N Engl J Med.* 2021. doi:  
173 10.1056/NEJMc2102017I.
- 174 10. Pfizer and BioNTech. Pfizer and BioNTech confirm high efficacy and no serious  
175 safety concerns through up to six months following second dose in updated topline  
176 analysis of landmark COVID-19 vaccine study. [https://www.pfizer.com/news/press-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious)  
177 [release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious)  
178 (accessed 10 Apr 2021).



179 Table. Baseline characteristics of the study cohort

180 Figure. SARS-CoV-2 incidence rate by time-period following the first dose of BNT162b2  
181 vaccination.

182 Panel A, SARS-CoV-2 infection incidence rate (per 100,000 person-days), Panel B, Severe  
183 COVID-19 incidence rate (per 100,000 person-days).

184 COVID-19, Coronavirus Disease 2019; CI, confidence interval; IRR, incidence rate ratio;

185 SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2. I bars indicate 95%  
186 confidence intervals.

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205 **Table. Baseline characteristics of the study cohort**

	<b>Total study cohort (n = 199,219)</b>	<b>Group without SARS-CoV-2 infection (n = 197,342 )</b>	<b>Group with SARS-CoV-2 infection (n = 1,877)</b>	<b>P value</b>
BNT162b2 doses received				
One dose	129,462 (65%)	129,950 (65%)	1512 (80.5%)	
Two doses	69,757 (35%)	69, 392 (35%)	365 (19.5%)	
Female sex	83,034 (41.7%)	82,214 (41.7%)	820 (43.7%)	0.076
Age (years)	42 (33–55)	42 (33–55)	44 (35–54)	<0.001
Age groups (years)				
16–24	13,826 ( 6.9%)	13,764 (7%)	62 (3.3%)	
25–34	43,302 (21.7%)	42,934 (21.8%)	368 (19.6%)	
35–44	51,934 (26.1%)	51,384 (26%)	550 (29.3%)	
45–54	39,274 (19.7%)	38,823 (19.7%)	451 (24%)	
55–64	31,257 (15.7%)	30,978 (15.7%)	279 (14.9%)	
≥65	19,626 (9.9%)	19,459 (9.9%)	167 (8.9%)	
Co-existing medical conditions				
Diabetes Mellitus	39,994 (20.1%)	39,550 (20%)	444 (23.7%)	<0.001
Hypertension	42,994 (21.6%)	42,512 (21.5%)	482 (25.7%)	<0.001
Chronic heart disease	10,308 (5.2%)	10,190 (5.2%)	118 (6.3%)	<0.029
Chronic lung disease	19,477 (9.8%)	19,270 (9.8%)	207 (11%)	0.067
Chronic kidney disease	4,272 (2.1%)	4,209 (2.13%)	63 (3.4%)	<0.001
Chronic liver disease	1,781 (0.9%)	1,754 (0.9%)	27 (1.4%)	0.012
Malignant disease	3,724 (1.9%)	3,691 (1.9%)	33 (1.8%)	0.72
Organ transplant recipient	653 ( 0.33%)	640 ( 0.32%)	13 ( 0.69%)	0.005



206 Data are presented as number (%) or median (interquartile range). P values were derived from Pearson's chi-

207 squared or Wilcoxon rank-sum test, as appropriate.

208

209

210



211